| Dr Mohammed Jamil Ahmed Khan, MD | |
|
1206 Richardson St, Port Huron, MI 48060-3549 | |
| (810) 984-4340 | |
| (810) 984-2303 |
| Full Name | Dr Mohammed Jamil Ahmed Khan |
|---|---|
| Gender | Male |
| Speciality | Allergy & Immunology |
| Location | 1206 Richardson St, Port Huron, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013907328 | NPI | - | NPPES |
| 2108970 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 4301031939 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohammed Jamil Ahmed Khan, MD 1206 Richardson St, Port Huron, MI 48060-3549 Ph: (810) 984-4340 | Dr Mohammed Jamil Ahmed Khan, MD 1206 Richardson St, Port Huron, MI 48060-3549 Ph: (810) 984-4340 |
News Archive
Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway.
Poor communication systems at nursing homes can lead to serious injury for residents who are not tended to in a timely manner. A new smartwatch app being developed at Binghamton University could help certified nursing assistants (CNAs) respond to alerts more quickly and help prevent falls.
For the first time, a minimally invasive transcatheter valve - tested by Baylor Research Institute in Dallas (BRI) - has been shown to save more lives than open-heart surgery, according to new research revealed at the American College of Cardiology's 2014 Scientific Sessions and published in The New England Journal of Medicine.
Alere Inc., a leading global provider of point-of-care rapid diagnostic and health information solutions, today announced the availability in Europe of the Alere i Influenza A & B test, the first and only molecular test to detect and differentiate influenza A and B virus in less than 15 minutes. The test is now commercially available in Austria, France, Spain, Switzerland, Germany, Italy and the UK.
New research suggests that if parents want to keep alcohol away from their middle school children, the best place to start is at home.
› Verified 2 days ago